Sensorion

152 articles about Sensorion

• Sensorion Hosting Key Opinion Leader Call with Dr. Michael Hoffer on Sudden Sensorineural Hearing Loss and SENS-401 as a Potential Treatment Option on July 23, 2020

  7/16/2020

  Sensorion announces it will host a key opinion leader call on Sudden Sensorineural Hearing Loss and SENS-401 as a potential treatment option on Thursday, July 23, 2020 at 12:30pm Eastern Time.

• 

  BioSpace Movers & Shakers, July 10

  7/10/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Sensorion Appoints Dr Edwin Moses, Former Ablynx CEO, as Chairman of the Board

  7/6/2020

  Sensorion a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the appointment of Edwin Moses, former Chief Executive Officer of Ablynx, as Chairman of its Board of Directors.

• Sensorion Announces Initiation of Coverage by US Investment Bank Chardan with a “Buy” Recommendation

  6/17/2020

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the healthcare investment bank Chardan has initiated analyst coverage of Sensorion.

• 

  BioSpace Global Roundup, June 11

  6/11/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

• Sensorion Announces Positive Preliminary Preclinical Data From Its Otoferlin Gene Therapy Program

  6/9/2020

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces promising new preliminary data in non-human primates from its ongoing gene therapy program targeting the Otoferlin encoding gene.

• Sensorion to attend Citi European Healthcare Conference - June 04, 2020

  6/4/2020

  Sensorion a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces it will attend the Citi European Healthcare Conference, held June 16-17.

• Sensorion Publishes Results of General Assembly Resolutions - May 21, 2020

  5/21/2020

  Sensorion a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced the results of resolutions presented at its General Assembly on May 20, 2020 and made them available on the dedicated section of its website.

• Sensorion Announces It Will Hold Its General Assembly on May 20, 2020 Behind Closed Doors Alongside the Publication of Its 2019 Annual Financial Report

  4/29/2020

  Sensorion a pioneering clinical-stage biotech company that specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that its Board of Directors has approved the procedure for holding this year’s General Assembly behind closed doors on Wednesday, May 20, 2020.

• Sensorion reschedules General Assembly to May 20

  4/24/2020

  Sensorion a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, rescheduled its General Assembly to Wednesday, May 20, 2020.

• Sensorion Reports Full-year 2019 Financial Results and Business Update

  4/2/2020

  Sensorion announces its full-year 2019 financial results and provides an update on its business activities and outlook for 2020.

• Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment

  3/13/2020

  Sensorion announced today an update on timelines for the ongoing Phase 2 study of SENS-401 to treat Sudden Sensorineural Hearing Loss (SSNHL). Patient recruitment rates from this trial now indicate

• 

  BioSpace Movers & Shakers, Feb. 21

  2/21/2020

  Biopharma and life sciences companies strengthen their leadership teams and board with this week's Movers & Shakers.

• Sensorion appoints gene therapy expert Dr Géraldine Honnet as Chief Medical Officer

  2/19/2020

  Sensorion, a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the appointment of gene therapy expert Géraldine Honnet MD, as Chief Medical Officer.

• Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study

  2/17/2020

  New sites to recruit voluntary military personnel in ongoing Phase 2 study in Sudden Sensorineural Hearing Loss

• Sensorion Announces the Full Conversion of Sofinnova Partners Convertible Bonds Into Ordinary Shares

  2/13/2020

  Sofinnova Crossover I SLP converted into ordinary shares of the Company all of the 7,500,000 convertible bonds (“CBs”) it had subscribed for in June 2019

• Sensorion Announces the Full Conversion of Invus Convertible Bonds Into Ordinary Shares

  2/10/2020

  Sensorion, a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces Invus Public Equities LP converted into ordinary shares all the convertible bonds it had subscribed for in June 2019.

• Sensorion to Attend and Present at LSX World Congress 2020

  2/3/2020

  Sensorion, a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces it will attend and present at the LSX World Congress 2020, held February 4-5 in London.

• Sensorion Presents New SENS-401 Preclinical Data at ARO Midwinter Meeting 2020

  1/30/2020

  Poster and oral presentation highlight potential to significantly reduce hearing loss from chronic noise exposure in a rat model

• Sensorion Announces its Presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference

  1/10/2020

  Sensorion announces that its management team, including CEO Nawal Ouzren and CBO Juergen Heitmann, will be present in San Francisco, USA, during the 38th annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2020.